The sense and nonsense of regression modeling for increasing precision of clinical trials

Clinical Pharmacology and Therapeutics

Volumn 74, Issue 3, 2003, Pages 295-297

  Cleophas, Ton J ^a  

^a European Interuniversity   (France)

Author keywords

[No Author keywords available]

Indexed keywords

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO; PRAVASTATIN;

ACCURACY; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; DRUG EFFICACY; HUMAN; HYPERCHOLESTEROLEMIA; LETTER; LOGISTIC REGRESSION ANALYSIS; MULTIPLE REGRESSION; PRIORITY JOURNAL; REGRESSION ANALYSIS; VARIANCE;

ALGORITHMS; CHOLESTEROL, LDL; CLINICAL TRIALS; HUMANS; LIPOPROTEINS, LDL; MODELS, STATISTICAL; RANDOMIZED CONTROLLED TRIALS; REGRESSION ANALYSIS; SOFTWARE;

EID: 0042332247     PISSN: 00099236     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0009-9236(03)00164-4     Document Type: Letter

References (3)

1. Feinstein AR. Statistical reductionism and clinicians' delinquencies in humanistic research. Clin Pharmacol Ther 1999;66:2-8.
2. Jonsson EN, Sheiner LB. More efficient clinical trials through use of scientific model-based statistical tests. Clin Pharmacol Ther 2002;72:603-14.
3. Jukema JW, Bruschke AV, van Boven AJ, Reiber JH, Bal ET, Zwinderman AH, et al. Effects of lipid lowering by pravastatin on progression and regression of coronary artery disease in symptomatic men with normal to moderately elevated serum cholesterol levels. The Regression Growth Evaluation Statin Study (REGRESS). Circulation 1995;91:2528-40.